Method for detecting concentration of tigecycline in blood plasma

A technology of tigecycline and plasma, which is applied to measurement devices, instruments, scientific instruments, etc., can solve the problem that municipal hospitals do not have mass spectrometer detectors, etc., and achieve the effects of high sensitivity and low cost
CN108469474AInactive Publication Date: 2018-08-31LIUZHOU CITY HEALTHCARE HOSPITAL FOR WOMEN & CHILDREN
5 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
LIUZHOU CITY HEALTHCARE HOSPITAL FOR WOMEN & CHILDREN
Publication Date
2018-08-31
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of in-vivo medicine detection, in particular to a method for detecting the concentration of tigecycline in blood plasma. According to the method for detecting the concentration of tigecycline in the blood plasma, ranitidine is adopted as an internal standard substance, and a high-performance liquid chromatograph is adopted for calculating the concentration of tigecycline in the blood plasma according to peak areas by means of an internal standard method under a certain chromatographic condition. The high-performance liquid chromatograph is adopted for detecting the concentration of tigecycline in the blood plasma, and the detection limitation can reach 0.028 microgram / mL. The method has the advantages of being high in accuracy and sensitivity, simple, high in detection speed and the like.
Need to check novelty before this filing date? Find Prior Art

Description

【Technical field】

[0001] The invention relates to the technical field of in vivo drug detection, in particular to a method for detecting the concentration of tigecycline in blood plasma. 【Background technique】

[0002] Tigecycline (TGC) is a glycylphthalein tetracycline antibacterial drug, which binds to the 305 subunit of the bacterial ribosome to block protein synthesis, thereby exerting an antibacterial effect. TGC is mainly used clinically to treat a variety of serious infections caused by Gram-positive bacteria and Gram-negative bacteria (except Pseudomonas aeruginosa), especially serious infections caused by multidrug-resistant bacteria and pan-drug-resistant bacteria . TGC is widely distributed after entering the human body, 59% of its dose is excreted through bile, and 33% is excreted through the kidneys. Patients with hepatic insufficiency need to adjust the dose, while patients with renal insufficiency do not need to adjust the dose. The situation of bacterial dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More